MiMedx Group (NASDAQ:MDXG) Hits New 1-Year Low - Should You Sell?

Key Points

• Shares of MiMedx hit a new 52‑week low of $4.08 (last $4.1050) on Wednesday, trading below the 50‑day ($4.96) and 200‑day ($6.25) moving averages.
• Analysts are mostly positive—five Buys and one Hold—giving an average rating of Moderate Buy with a consensus price target of $9.60.
• Fundamentals showed a quarter beat (EPS $0.14 vs. $0.09 est., revenue $118.1M vs. $106.8M), the stock has a market cap of ~$609M and P/E of 12.8, and institutional investors own about 79% of shares.

Shares of MiMedx Group, Inc (NASDAQ:MDXG - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.08 and last traded at $4.1050, with a volume of 296123 shares changing hands. The stock had previously closed at $4.13.

Wall Street Analysts Forecast Growth

MDXG has been the topic of a number of analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of MiMedx Group in a research report on Monday, December 29th. Citizens Jmp assumed coverage on MiMedx Group in a research note on Monday, February 23rd. They issued a "market outperform" rating and a $10.00 target price for the company. Cantor Fitzgerald reduced their price target on MiMedx Group from $12.00 to $8.00 and set an "overweight" rating on the stock in a report on Tuesday, February 17th. Lake Street Capital lowered their price target on shares of MiMedx Group from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, January 20th. Finally, Citigroup initiated coverage on shares of MiMedx Group in a research report on Monday, February 23rd. They set a "market outperform" rating for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, MiMedx Group presently has an average rating of "Moderate Buy" and a consensus price target of $9.60.

MiMedx Group Stock Down 0.7%

The stock has a market capitalization of $609.14 million, a price-to-earnings ratio of 12.81 and a beta of 1.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. The business has a fifty day moving average of $4.96 and a 200 day moving average of $6.25.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The company had revenue of $118.10 million during the quarter, compared to analysts' expectations of $106.78 million. As a group, equities analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Institutional Trading of MiMedx Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC raised its stake in shares of MiMedx Group by 89.5% in the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company's stock valued at $25,498,000 after acquiring an additional 1,725,458 shares during the period. Divisadero Street Capital Management LP boosted its position in shares of MiMedx Group by 362.9% during the 2nd quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company's stock worth $1,364,000 after purchasing an additional 175,000 shares during the period. Hussman Strategic Advisors Inc. acquired a new stake in MiMedx Group in the 3rd quarter valued at approximately $1,759,000. Trigran Investments Inc. increased its holdings in MiMedx Group by 10.4% in the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company's stock valued at $51,266,000 after purchasing an additional 790,901 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in MiMedx Group by 419.3% in the third quarter. SG Americas Securities LLC now owns 161,960 shares of the company's stock valued at $1,130,000 after purchasing an additional 130,769 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.